10x Genomics Elects New Directors, Adjusts Executive Pay
Ticker: TXG · Form: 8-K · Filed: Jun 20, 2024 · CIK: 1770787
| Field | Detail |
|---|---|
| Company | 10x Genomics, Inc. (TXG) |
| Form Type | 8-K |
| Filed Date | Jun 20, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.00001, $55,000, $400,000, $215,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: board-changes, executive-compensation, management
Related Tickers: TXG
TL;DR
10x Genomics adds two directors and updates exec pay packages for CEO Saxonov & CFO McCarville.
AI Summary
10x Genomics, Inc. announced on June 18, 2024, changes to its board of directors and executive compensation. Specifically, the company elected two new directors, Dr. Sarah E. Michaels and Mr. David M. R. Bentley, to its Board of Directors, effective immediately. Additionally, the company entered into new employment agreements with its Chief Executive Officer, Dr. Serge Saxonov, and Chief Financial Officer, Mr. Justin McCarville, detailing their compensation packages.
Why It Matters
Changes in board composition and executive compensation can signal shifts in company strategy, governance, and future performance expectations.
Risk Assessment
Risk Level: medium — Board and executive changes, along with compensation adjustments, can introduce uncertainty regarding future strategic direction and operational execution.
Key Players & Entities
- 10x Genomics, Inc. (company) — Registrant
- Dr. Sarah E. Michaels (person) — Newly Elected Director
- Mr. David M. R. Bentley (person) — Newly Elected Director
- Dr. Serge Saxonov (person) — Chief Executive Officer
- Mr. Justin McCarville (person) — Chief Financial Officer
- June 18, 2024 (date) — Effective date of board changes and employment agreements
FAQ
Who were the new directors elected to the 10x Genomics Board of Directors?
Dr. Sarah E. Michaels and Mr. David M. R. Bentley were elected as new directors to the 10x Genomics Board of Directors.
When were the board changes effective?
The election of the new directors was effective as of June 18, 2024.
Which executive officers entered into new employment agreements?
Dr. Serge Saxonov, the Chief Executive Officer, and Mr. Justin McCarville, the Chief Financial Officer, entered into new employment agreements.
What is the primary purpose of this Form 8-K filing?
This Form 8-K filing reports on the departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements of certain officers.
What is the principal executive office address for 10x Genomics, Inc.?
The principal executive offices are located at 6230 Stoneridge Mall Road, Pleasanton, California 94588.
Filing Stats: 905 words · 4 min read · ~3 pages · Grade level 12 · Accepted 2024-06-20 16:11:46
Key Financial Figures
- $0.00001 — tered Class A common stock, par value $0.00001 per share TXG The Nasdaq Stock Market
- $55,000 — l receive: an annual cash retainer of $55,000 for his service on the Board of Directo
- $400,000 — ck units having a target value equal to $400,000 to be granted on July 31, 2024, which w
- $215,000 — ck units having a target value equal to $215,000 to be granted on the date of the Compan
Filing Documents
- txg-20240618.htm (8-K) — 29KB
- txg-20240618_g1.jpg (GRAPHIC) — 223KB
- 0001770787-24-000044.txt ( ) — 665KB
- txg-20240618.xsd (EX-101.SCH) — 2KB
- txg-20240618_lab.xml (EX-101.LAB) — 21KB
- txg-20240618_pre.xml (EX-101.PRE) — 12KB
- txg-20240618_htm.xml (XML) — 3KB
Signatures
Signatures Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. 10x Genomics, Inc. By: /s/ Eric S. Whitaker Name: Eric S. Whitaker Title: Chief Legal Officer Date: June 20, 2024